Literature DB >> 10376615

Optimisation of antihypertensive treatment by crossover rotation of four major classes.

J E Dickerson1, A D Hingorani, M J Ashby, C R Palmer, M J Brown.   

Abstract

BACKGROUND: Most comparisons of antihypertensive drugs are undertaken in parallel groups. We undertook a crossover rotation of the four main classes of antihypertensive drugs, in untreated young hypertensive patients, to assess the response rate with monotherapy achieved by a systematic rotation.
METHODS: 56 patients, mean blood pressure 161/98 mm Hg, entered the rotation, of whom 36 received all four monthly cycles of treatment with an angiotensin-converting-enzyme (ACE) inhibitor (A), beta-blocker (B), calcium-channel blocker (C), and diuretic (D). Each patient's best drug was then repeated to assess repeatability. Two measures of individual variability in response were used. First, the value of rotation was measured by the increased proportion of patients reaching target blood pressure on their best drug versus their first drug. Second, we assessed whether the responses to each drug were correlated with each other.
FINDINGS: Significant variability in response was found. 20 of the 41 patients reaching target blood pressure (< or =140/90 mm Hg) failed to achieve this target on their first drug. Rotation increased from 22/56 (39%) to 41/56 (73%) the success of monotherapy (p=0.0001); in half the patients, blood-pressure on the best treatment was 135/85 mm Hg or less. There were significant correlations between the blood pressure responses to A and B (r=0.5, p<0.01), and C and D (r=0.6, p<0.001), but not between the other four pairings of treatments. The responses to the AB pair were, on average, at least 50% higher than those to the CD pair; this difference was highly significant by multivariate repeated-measures ANOVA.
INTERPRETATION: There is a marked variability in hypertensive patients' response to different antihypertensive drugs. The basis may be underlying variability in types of essential hypertension. Optimisation of treatment requires systematic rotation through several therapies; however, an "AB/CD" rule is proposed in which one of each of the two pairs of treatments is initially selected to abbreviate the rotation in routine practice.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10376615     DOI: 10.1016/s0140-6736(98)07614-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  73 in total

1.  New Canadian hypertension recommendations. So what?

Authors:  N R Campbell
Journal:  Can Fam Physician       Date:  2000-07       Impact factor: 3.275

Review 2.  Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension.

Authors:  M Ruzicka; F H Leenen
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Matching the right drug to the right patient in essential hypertension.

Authors:  M J Brown
Journal:  Heart       Date:  2001-07       Impact factor: 5.994

Review 4.  Selecting the right drug for initial antihypertensive therapy.

Authors:  A B Weder
Journal:  Curr Hypertens Rep       Date:  2000-02       Impact factor: 5.369

Review 5.  Why beta-blockers are not cardioprotective in elderly patients with hypertension.

Authors:  Ehud Grossman; Franz H Messerli
Journal:  Curr Cardiol Rep       Date:  2002-11       Impact factor: 2.931

Review 6.  Resistant hypertension and the Birmingham Hypertension Square.

Authors:  D C Felmeden; G Y Lip
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

7.  Decision support and safety of clinical environments.

Authors:  A H Morris
Journal:  Qual Saf Health Care       Date:  2002-03

8.  Drug treatment of hypertension: implications of ALLHAT.

Authors:  B Williams
Journal:  Heart       Date:  2003-06       Impact factor: 5.994

9.  Diuretic use in black patients with uncontrolled hypertension.

Authors:  Linda M Gerber; Samuel J Mann; Margaret V McDonald; Ya-Lin Chiu; Sridevi Sridharan; Penny H Feldman
Journal:  Am J Hypertens       Date:  2012-12-28       Impact factor: 2.689

10.  Pleiotropic effects of the acute and chronic inhibition of the renin-angiotensin system in hypertensives.

Authors:  K Stamatelopoulos; D Bramos; E Manios; E Alexaki; A Kaladaridou; G Georgiopoulos; E Koroboki; A Kolyviras; K Stellos; N Zakopoulos; S Toumanidis
Journal:  J Hum Hypertens       Date:  2013-11-28       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.